(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(morpholino)methanone | 1615699-89-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(morpholino)methanone
• 英文别名: 2,5,7,8-Tetramethyl-2-(morpholin-4-ylcarbonyl)chroman-6-ol；(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromen-2-yl)-morpholin-4-ylmethanone
• CAS: 1615699-89-2
• 化学式: C₁₈H₂₅NO₄
• 分子量: 319.401
• InChiKey: MCJPTWSIETYCSU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  23
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  59
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Treatment of mitochondrial diseases
  申请人：Walkinshaw Gail

  公开号：US20050065099A1

  公开（公告）日：2005-03-24

  The invention relates the method of treatment or amelioration of mitochondrial disorders such as Alzheimer's disease, Parkinson's disease, Friedreich's ataxia (FRDA), cerebellar ataxias, Leber's hereditary optic neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), Myoclonic Epilepsy with Ragged Red Fibers (MERFF), amyotrophic lateral sclerosis (ALS), motor neuron diseases, Huntington's disease, macular degeneration, and epilepsy, with chroman derivatives of Formula I or Formula II as described herein.

  这项发明涉及治疗或改善线粒体疾病，如阿尔茨海默病、帕金森病、弗里德雷希共济失调症（FRDA）、小脑共济失调、勒伯遗传性视神经病变（LHON）、线粒体肌病、脑病、乳酸中毒、中风（MELAS）、带有红色纤维的肌阵挛性癫痫（MERFF）、肌萎缩侧索硬化症（ALS）、运动神经元疾病、亨廷顿病、黄斑变性和癫痫等疾病的治疗方法，所述方法使用本文描述的FormuLA I或FormuLA II的类胡萝卜素衍生物。
• [EN] COMPOUNDS FOR PROTECTION OF CELLS<br/>[FR] COMPOSÉS POUR LA PROTECTION DES CELLULES
  申请人：SULFATEQ BV

  公开号：WO2014098586A1

  公开（公告）日：2014-06-26

  This invention is related to a compound with the structural formula (I). Wherein, R1, and R2 are independently selected from the group consisting of C1-C6 alkyl and is preferably methyl, ethyl, propyl or isopropyl; R3 is selected from the group consisting of CH2NHR9, C(=0)YR10, -CH20H; Formula (II).

  这项发明涉及具有结构式（I）的化合物。其中，R1和R2分别从C1-C6烷基组中选择，最好是甲基、乙基、丙基或异丙基；R3从CH2NHR9、C(=0)YR10、-CH20H组中选择；公式（II）。
• [EN] 6-HYDROXY-2,5,7,8-TETRAMETHYLCHROMAN-COMPOUNDS FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE AIRWAY DISEASES<br/>[FR] COMPOSÉS 6-HYDROXY-2,5,7,8-TETRAMÉTHYLCHROMAN- POUR LE TRAITEMENT DE MALADIES OBSTRUCTIVES CHRONIQUES DES VOIES RESPIRATOIRES
  申请人：SULFATEQ BV

  公开号：WO2015193365A1

  公开（公告）日：2015-12-23

  The present invention relates to compounds for the treatment of chronic obstructive airway diseases such as chronic obstructive pulmonary disease (COPD) or asthma or bronchiectasis. The present invention further relates to drug delivery devices suitable to be used in the treatment of chronic obstructive airway diseases such as a nebulizer comprising the present compounds. Specifically, the present invention relates to (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-1-yl)methanone or N,6-dihydroxy-2,5,7,8-tetramethylchroman-2-carboxamide or a pharmaceutically acceptable salt or base thereof for use in the treatment of chronic obstructive airway diseases, preferably chronic obstructive pulmonary disease (COPD) or asthma or bronchiectasis, more preferably chronic obstructive pulmonary disease (COPD).

  本发明涉及用于治疗慢性阻塞性气道疾病，如慢性阻塞性肺病（COPD）或哮喘或支气管扩张症的化合物。本发明还涉及适用于治疗慢性阻塞性气道疾病的药物给药装置，例如包含本发明化合物的雾化器。具体地，本发明涉及用于治疗慢性阻塞性气道疾病，尤其是慢性阻塞性肺病（COPD）或哮喘或支气管扩张症的（6-羟基-2,5,7,8-四甲基色素-2-基）（哌嗪-1-基）甲酮或N,6-二羟基-2,5,7,8-四甲基色素-2-甲酰胺或其药用可接受的盐或碱。
• [EN] COMPOUND FOR THE PROPHYLAXIS OR TREATMENT OF ORGAN DAMAGE<br/>[FR] COMPOSÉ POUR LA PROPHYLAXIE OU LE TRAITEMENT DE LÉSION D'ORGANE
  申请人：SULFATEQ BV

  公开号：WO2016188766A1

  公开（公告）日：2016-12-01

  The present invention relates to compounds for prophylaxis or treatment of organ damage by restoring endothelial function and/or inhibiting reactive oxygen species production and especially to compounds for prophylaxis or treatment of diabetic kidney damage. Specifically, the present invention relates to 6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-1-yl)methanone or N,6-dihydroxy-2,5,7,8-tetramethylchroman-2-carboxamide or a pharmaceutically acceptable salt or base thereof for use in the prophylaxis or treatment of organ damage by restoring endothelial function and/or inhibiting reactive oxygen species production and especially diabetic kidney organ damage.

  本发明涉及用于预防或治疗器官损伤的化合物，通过恢复内皮功能和/或抑制活性氧产生，特别是用于预防或治疗糖尿病肾损伤的化合物。具体而言，本发明涉及6-羟基-2,5,7,8-四甲基色烯-2-基)(哌嗪-1-基)甲酮或N,6-二羟基-2,5,7,8-四甲基色烯-2-羧酰胺或其药用可接受的盐或碱，用于通过恢复内皮功能和/或抑制活性氧产生，特别是糖尿病肾器官损伤的预防或治疗。
• TREATMENT OF MITOCHONDRIAL DISEASES
  申请人：Ampere Life Sciences, Inc.

  公开号：US20130267538A1

  公开（公告）日：2013-10-10

  The invention relates the method of treatment or amelioration of mitochondrial disorders such as Alzheimer's disease, Parkinson's disease, Friedreich's ataxia (FRDA), cerebellar ataxias, Leber's hereditary optic neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), Myoclonic Epilepsy with Ragged Red Fibers (MERFF), amyotrophic lateral sclerosis (ALS), motor neuron diseases, Huntington's disease, macular degeneration, and epilepsy, with chroman derivatives of Formula I or Formula II as described herein.

  本发明涉及使用式I或式II所描述的色酮衍生物的治疗或改善线粒体疾病的方法，例如阿尔茨海默病、帕金森病、弗里德雷希共济失调症（FRDA）、小脑共济失调、勒伯遗传性视神经病变（LHON）、线粒体肌病、脑病、乳酸中毒、中风（MELAS）、带红纤维的肌阵挛性癫痫（MERFF）、肌萎缩侧索硬化症（ALS）、运动神经元疾病、亨廷顿病、黄斑退化和癫痫。